Intest Res 2026;24(2):366-375

Supplementary Table 2. Time between the Treatment Intensification Date and Treatment Change or Intensification in Patients with Steroid-Dependent Ulcerative Colitis

Treatment change or intensification after the treatment intensification date	Thiopurine treatment			Advanced therapy		
	Patients, n	Days, mean ± SD	Days, median (IQR)	Patients, n	Days, mean ± SD	Days, median (IQR)
Thiopurine						
Azathioprine	0	-	-	23	107.8 ± 93.2	81.0 (42.0–146.0)
6-Mercaptopurine	3	93.0 ± 60.8	100.0 (29.0–150.0)	1	31.0	31.0 (31.0–31.0)
Advanced therapy						
Adalimumab	13	125.2 ± 79.8	107.0 (92.0–148.0)	2	212.0 ± 28.3	212.0 (192.0–232.0)
Infliximab	7	240.3 ± 122.2	218.0 (112.0–375.0)	3	77.0 ± 61.7	72.0 (18.0–141.0)
Golimumab	6	125.0 ± 68.9	106.0 (82.0–189.0)	3	158.7 ± 84.5	133.0 (90.0–253.0)
Ustekinumab	0	-	-	1	309.0	309.0 (309.0–309.0)
Vedolizumab	10	179.0 ± 109.0	172.5 (68.0–291.0)	3	188.0 ± 172.4	107.0 (71.0–386.0)
Tofacitinib	2	110.0 ± 62.2	110.0 (66.0–154.0)	1	126.0	126.0 (126.0–126.0)
Filgotinib	0	-	-	0	-	-
Upadacitinib	0	-	-	0	-	-
Immunomodulator						
Cyclosporine	0	-	-	0	-	
Tacrolimus	5	127.6 ± 60.4	142.0 (70.0–148.0)	0	-	

SD, standard deviation; IQR, interquartile range.

https://doi.org/10.5217/ir.2025.00032